- Brexpiprazole - ALZFORUM
Brexpiprazole is approved in the United States for the treatment of schizophrenia, and as an add-on therapy for depression It was the first treatment approved for agitation associated with dementia in patients with Alzheimer's disease In addition, it is being tested in people with bipolar and post-traumatic stress disorder
- Efficacy and Safety of Brexpiprazole for the Treatment of . . . - ALZFORUM
Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials Am J Geriatr Psychiatry 2020 Apr;28 (4):383-400
- Efficacy and safety of brexpiprazole for the treatment of . . . - ALZFORUM
Marinheiro G, Dantas JM, Mutarelli A, Menegaz de Almeida A, Monteiro GA, Zerlotto DS, Telles JP Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's disease: a meta-analysis of randomized controlled trials Neurol Sci 2024 May 20; PubMed
- FDA Approves Rexulti for Agitation in Alzheimer’s | ALZFORUM
Brexpiprazole is a derivative of aripiprazole, aka Abilify, an atypical antipsychotic As a group, such drugs have a sketchy track record in treating agitation in AD, and their side effects had prompted the agency to issue “black box” warnings (Steinberg and Lyketsos, 2012)
- A critical review of brexpiprazole oral tablets as the first drug . . .
A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease Expert Rev Neurother 2025 Jan;25 (1):5-13
- Brexpiprazole-related tardive dystonia in a young patient with . . .
Ebina T, Iwamoto K, Ikeda M Brexpiprazole-related tardive dystonia in a young patient with schizophrenia: A case report Psychiatry Clin Neurosci 2024 May;78 (5):334-335
- Brexpiprazole for the Treatment of Agitation in Alzheimer . . . - ALZFORUM
Lee D, Slomkowski M, Hefting N, Chen D, Larsen KG, Kohegyi E, Hobart M, Cummings JL, Grossberg GT Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial JAMA Neurol 2023 Dec 1;80 (12):1307-1316 PubMed
- Safety assessment of Brexpiprazole: Real-world adverse event analysis . . .
Jiang Y, Zhou L, Shen Y, Zhou Q, Ji Y, Zhu H Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database J Affect Disord 2024 Feb 1;346:223-229
|